Aceragen - About the company
Aceragen is an acquired company based in Durham (United States), founded in 2021. It operates as a Developer of therapeutics for rare and orphan diseases. Aceragen has raised an undisclosed amount in funding. The company has 286 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.
Company Details
Developer of therapeutics for rare and orphan diseases. The lead product of the company is ACG-801 a recombinant human acid ceramidase as an investigational therapy for Farber disease. Other products include ACG-701 for Melioidosis and cystic fibrosis and AGC-301 for cancer indications.
- Website
- aceragen.com
- Email ID
- *****@aceragen.com
- Registered Address
- Exton, Pennsylvania
Key Metrics
Founded Year
2021
Location
Durham, United States
Stage
Acquired
Latest Funding Round
Investors
Ranked
132nd among 286 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2022
Employee Count
23 as on Jul 01, 2024
Investment & Acquisitions
Exit Details
Acquired
Legal entities associated with Aceragen
Aceragen is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ACERAGEN, INC. CIN: 861838 , United States, Active | Jan 18, 2021 | $1M - $10M (As on Dec 31, 2022) | - | - |
Idera Pharmaceuticals, Inc. CIN: 43072298 , United States, Active | Dec 26, 999 | $1M - $10M (As on Dec 31, 2019) | 6 (As on Dec 31, 2022) | - |
Aceragen's acquisition details
Aceragen got acquired on Sep 28, 2022.
Click here to take a look at Aceragen's acquisition in detail
Sign up to download Aceragen's company profile
Aceragen's funding and investors
Aceragen has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jan 06, 2022 for $*****. 1 investor participated in its latest round. Aceragen has 2 institutional investors.
Here is the list of recent funding rounds of Aceragen:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 06, 2022 | 2420027 | Grant (prize money) | 6722649 | 5443086 | 4210426 | 3160917 |
View details of Aceragen's funding rounds and investors
Aceragen's founders and board of directors
Founder? Claim ProfileAceragen's employee count trend
Aceragen has 23 employees as of Jul 24. Here is Aceragen's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aceragen's Competitors and alternates
Top competitors of Aceragen include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Aceragen, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | BridgeBio 2015, Palo Alto (United States), Public | Developer of therapeutics for the treatment of genetic diseases | $434M | 82/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 81/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 73/100 | |
4th | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 72/100 | |
5th | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 72/100 | |
6th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 69/100 | |
7th | Ionis 1989, United States, Public | Developer of RNA-targeted medicines for various diseases | - | 69/100 | |
8th | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 68/100 | |
9th | Cabaletta Bio 2017, Radnor (United States), Public | Developer of CAAR T cells for B cell-mediated autoimmune diseases | $88.3M | 68/100 | |
10th | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 68/100 | |
132nd | Aceragen 2021, Durham (United States), Acquired | Developer of therapeutics for rare and orphan diseases | - | 38/100 |
Looking for more details on Aceragen's competitors? Click here to see the top ones
Aceragen's Investments and acquisitions
Aceragen has acquired Arrevus. Aceragen has not made any investments as of now.Reports related to Aceragen
Here is the latest report on Aceragen's sector:
News related to Aceragen
•
•
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingGlobeNewswire•May 31, 2023•Aceragen, Nasdaq
•
Idera Pharmaceuticals completes acquisition of AceragenSeeking Alpha•Sep 29, 2022•Aceragen, NovaQuest Capital Management
•
Durham CEO now leads public company following acquisitionThe Business Journals•Sep 28, 2022•Aceragen
•
Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosisGlobeNewswire•Jun 15, 2022•Aceragen
•
•
Aceragen Acquires Arrevus, Expands Late-Stage Rare Disease PipelineBioPharm International•Nov 03, 2021•Aceragen, Arrevus
•
Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuestBusiness Wire•May 03, 2021•Aceragen, Enzyvant
Are you a Founder ?
FAQs about Aceragen
Explore our recently published companies
- Tibnology - India based, Unfunded company
- SS Concrete Coatings - Freeport based, Unfunded company
- S K Reality - Pune based, Unfunded company
- Roemo Fliesen - Germany based, 1991 founded, Unfunded company
- Rocky Mountain Trades - Logan based, Unfunded company
- Roberta Flanagan Realtor - Merced based, 1960 founded, Unfunded company
